Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline Nasal Spray for Dry Eye and Meibomian Gland Dysfunction
NCT07606625Phase 4Recruiting
- Sponsor
- University of California, Berkeley
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of varenicline in dry eye disease (DED) and meibomian gland dysfunction (MGD), sponsored by University of California, Berkeley. Primary endpoints: Change in tear lipid layer thickness at 3 months and Change in tear thinning rate at 3 months. Started Mar 2026; status: recruiting.
02
Drugs
varenicline
03
Conditions
dry eye disease (DED)meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT07606625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606625.